Tru-Khang T. Dinh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tru-Khang T. Dinh has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Alan D. D'Andrea
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
2 shared publications - Eric Ford
University of Washington
2 shared publications George R. Schade
Department of Urology, University of Washington, Seattle, Washington
2 shared publicationsJay J. Liao
Department of Radiation Oncology, University of Washington, Seattle, Washington
2 shared publicationsMeghan W. Macomber
Sutter Health Radiation Oncology
2 shared publicationsRamesh Rengan
Department of Radiation Oncology, University of Washington, Seattle, Washington
2 shared publications
Latest Publications
- 6 January 2023
- Published by Elsevier in Physica Medica
- Vol. 106, 102526
Cobalt compensator-based IMRT device: A treatment planning study of head and neck cases
- 6 January 2023
- Published by Elsevier in Physica Medica
- Vol. 106, 102526
Cobalt compensator-based IMRT device: A treatment planning study of head and neck cases
- 1 November 2021
- Published by Elsevier in Brachytherapy
- Vol. 20 (6) , 1180-1186
Management of locally advanced mesonephric carcinoma of the cervix in the setting of Mullerian Duct anomaly spectrum and unilateral renal agenesis: A case report and review of the literature
- 1 November 2021
- Published by Elsevier in Brachytherapy
- Vol. 20 (6) , 1180-1186
Management of locally advanced mesonephric carcinoma of the cervix in the setting of Mullerian Duct anomaly spectrum and unilateral renal agenesis: A case report and review of the literature
- 25 March 2021
- Published by Springer Nature
- p. 189-207
Postoperative Radiotherapy for Prostate Cancer
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , 564-571
National Quality Improvement Participation Among US Radiation Oncology Facilities: Compliance with Guideline-Concordant Palliative Radiation Therapy for Bone Metastases
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , 564-571
National Quality Improvement Participation Among US Radiation Oncology Facilities: Compliance with Guideline-Concordant Palliative Radiation Therapy for Bone Metastases
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , 635-643
Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared to Rectal Balloon Immobilization After Proton Beam Radiation Therapy for Localized Prostate Cancer: A Retrospective Observational Study
- 1 November 2020
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 108 (3) , 635-643
Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared to Rectal Balloon Immobilization After Proton Beam Radiation Therapy for Localized Prostate Cancer: A Retrospective Observational Study
- Open Access
- 1 July 2020
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 5 (4) , 544-547
Radiation Therapy in King County, Washington During the COVID-19 Pandemic: Balancing Patient Care, Transmission Mitigation, and Resident Training
- 1 July 2020
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 5 (4) , 544-547
Open AccessRadiation Therapy in King County, Washington During the COVID-19 Pandemic: Balancing Patient Care, Transmission Mitigation, and Resident Training
- 1 March 2020
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 7 (2) , 158-161
A Case of Rectal Ulcer during Intensity Modulated Radiotherapy for Prostate Cancer Using Hydrogel Spacer
We report a case of a severely symptomatic rectal ulcer, a CTCAE (Common Terminology Criteria for Adverse Events) grade 3 complication, after intensity modulated radiotherapy for prostate c...
- 1 March 2020
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 7 (2) , 158-161
A Case of Rectal Ulcer during Intensity Modulated Radiotherapy for Prostate Cancer Using Hydrogel Spacer
We report a case of a severely symptomatic rectal ulcer, a CTCAE (Common Terminology Criteria for Adverse Events) grade 3 complication, after intensity modulated radiotherapy for prostate c...
- 1 July 2019
- Published by Elsevier in Practical Radiation Oncology
- Vol. 9 (4) , e407-e416
Durable Improvement in Patient Safety Culture Over 5 Years With Use of High-volume Incident Learning System
- 1 July 2019
- Published by Elsevier in Practical Radiation Oncology
- Vol. 9 (4) , e407-e416
Durable Improvement in Patient Safety Culture Over 5 Years With Use of High-volume Incident Learning System
- Open Access
- 7 February 2018
- Published by Springer Nature in Cell Death Discovery
- Vol. 4 (1) , 10
NF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair
Despite optimal chemotherapy, radiotherapy (RT), and/or surgery, non-small-cell lung carcinoma (NSCLC) remains the leading cause of cancer-related death in the US and worldwide. Thoracic RT, a mainstay in the treatment of locally advanced NSCLC, is often restricted in efficacy by a therapeutic index limited by sensitivity of tissues surrounding the malignancy. Therefore, radiosensitizers that can improve the therapeutic index are a vital unmet need. Inhibition of the NF-κB pathway is a proposed mechanism of radiosensitization. Here we demonstrate that inhibition of the canonical NF-κB pathway by dimethylaminoparthenolide (DMAPT) radiosensitizes NSCLC by blocking DNA double-strand break (DSB) repair. NF-κB inhibition results in significant impairment of both homologous recombination (HR) and non-homologous end joining (NHEJ), as well as reductions in ionizing radiation (IR)-induced DNA repair biomarkers. NF-κB inhibition by DMAPT shows preclinical potential for further investigation as a NSCLC radiosensitizer.
- 7 February 2018
- Published by Springer Nature in Cell Death Discovery
- Vol. 4 (1) , 10
Open AccessNF-κB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair
Despite optimal chemotherapy, radiotherapy (RT), and/or surgery, non-small-cell lung carcinoma (NSCLC) remains the leading cause of cancer-related death in the US and worldwide. Thoracic RT, a mainstay in the treatment of locally advanced NSCLC, is often restricted in efficacy by a therapeutic index limited by sensitivity of tissues surrounding the malignancy. Therefore, radiosensitizers that can improve the therapeutic index are a vital unmet need. Inhibition of the NF-κB pathway is a proposed mechanism of radiosensitization. Here we demonstrate that inhibition of the canonical NF-κB pathway by dimethylaminoparthenolide (DMAPT) radiosensitizes NSCLC by blocking DNA double-strand break (DSB) repair. NF-κB inhibition results in significant impairment of both homologous recombination (HR) and non-homologous end joining (NHEJ), as well as reductions in ionizing radiation (IR)-induced DNA repair biomarkers. NF-κB inhibition by DMAPT shows preclinical potential for further investigation as a NSCLC radiosensitizer.
- Open Access
- 27 April 2016
- Published by Springer Nature in Radiation Oncology
- Vol. 11 (1) , 1-11
Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer
Risk of normal tissue toxicity limits the amount of thoracic radiation therapy (RT) that can be routinely prescribed to treat non-small cell lung cancer (NSCLC). An early biomarker of response to thoracic RT may provide a way to predict eventual toxicities—such as radiation pneumonitis—during treatment, thereby enabling dose adjustment before the symptomatic onset of late effects. MicroRNAs (miRNAs) were studied as potential serological biomarkers for thoracic RT. As a first step, we sought to identify miRNAs that correlate with delivered dose and standard dosimetric factors. We performed miRNA profiling of plasma samples obtained from five patients with Stage IIIA NSCLC at five dose-points each during radical thoracic RT. Candidate miRNAs were then assessed in samples from a separate cohort of 21 NSCLC patients receiving radical thoracic RT. To identify a cellular source of circulating miRNAs, we quantified in vitro miRNA expression intracellularly and within secreted exosomes in five NSCLC and stromal cell lines. miRNA profiling of the discovery cohort identified ten circulating miRNAs that correlated with delivered RT dose as well as other dosimetric parameters such as lung V20. In the validation cohort, miR-29a-3p and miR-150-5p were reproducibly shown to decrease with increasing radiation dose. Expression of miR-29a-3p and miR-150-5p in secreted exosomes decreased with radiation. This was concomitant with an increase in intracellular levels, suggesting that exosomal export of these miRNAs may be downregulated in both NSCLC and stromal cells in response to radiation. miR-29a-3p and miR-150-5p were identified as circulating biomarkers that correlated with delivered RT dose. miR-150 has been reported to decrease in the circulation of mammals exposed to radiation while miR-29a has been associated with fibrosis in the human heart, lungs, and kidneys. One may therefore hypothesize that outlier levels of circulating miR-29a-3p and miR-150-5p may eventually help predict unexpected responses to radiation therapy, such as toxicity.
- 27 April 2016
- Published by Springer Nature in Radiation Oncology
- Vol. 11 (1) , 1-11
Open AccessCirculating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer
Risk of normal tissue toxicity limits the amount of thoracic radiation therapy (RT) that can be routinely prescribed to treat non-small cell lung cancer (NSCLC). An early biomarker of response to thoracic RT may provide a way to predict eventual toxicities—such as radiation pneumonitis—during treatment, thereby enabling dose adjustment before the symptomatic onset of late effects. MicroRNAs (miRNAs) were studied as potential serological biomarkers for thoracic RT. As a first step, we sought to identify miRNAs that correlate with delivered dose and standard dosimetric factors. We performed miRNA profiling of plasma samples obtained from five patients with Stage IIIA NSCLC at five dose-points each during radical thoracic RT. Candidate miRNAs were then assessed in samples from a separate cohort of 21 NSCLC patients receiving radical thoracic RT. To identify a cellular source of circulating miRNAs, we quantified in vitro miRNA expression intracellularly and within secreted exosomes in five NSCLC and stromal cell lines. miRNA profiling of the discovery cohort identified ten circulating miRNAs that correlated with delivered RT dose as well as other dosimetric parameters such as lung V20. In the validation cohort, miR-29a-3p and miR-150-5p were reproducibly shown to decrease with increasing radiation dose. Expression of miR-29a-3p and miR-150-5p in secreted exosomes decreased with radiation. This was concomitant with an increase in intracellular levels, suggesting that exosomal export of these miRNAs may be downregulated in both NSCLC and stromal cells in response to radiation. miR-29a-3p and miR-150-5p were identified as circulating biomarkers that correlated with delivered RT dose. miR-150 has been reported to decrease in the circulation of mammals exposed to radiation while miR-29a has been associated with fibrosis in the human heart, lungs, and kidneys. One may therefore hypothesize that outlier levels of circulating miR-29a-3p and miR-150-5p may eventually help predict unexpected responses to radiation therapy, such as toxicity.